Drug Database
Back to search

Netherlands· NL-f7d2ae99176a

Neupogen Singleject 48 x 1000000 E/0,5 ml, oplossing voor injectie in een voorgevulde spuit, 0,96 mg/ml

A filgrastim product containing filgrastim, registered in Netherlands by Amgen Europe B.V.. The same ATC class is registered in 17 of our 19 countries.

ATC L03AA02

Checked against CBG-MEB (Netherlands) on

Informational only — not a medical device.

SOURCE REGISTER · NLCBG-MEB (Netherlands)normalisedNeupogen Singleject 48 x 1000000 E/0,…ATCL03AA02REGISTER NO.NL-f7d2ae99176aPACKS LISTED1CHECKEDSeptember 29, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about filgrastimAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Filgrastim is registered in 17 of 19 countries.

Countries holding a registration under ATC L03AA02 (filgrastim), each read from that country’s own register.

  • This record: Netherlands, from CBG-MEB (Netherlands)
  • 10 of them publish a price we can compare per daily dose
Search filgrastim products by name

Filgrastim · ATC L03AA02

17 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Germany
  • Icelandprice
  • Ireland
  • Italyprice
  • Netherlands
  • Norwayprice
  • Polandprice
  • Sweden
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

CBG-MEB (Netherlands)
Active substance
FILGRASTIM
Manufacturer
Amgen Europe B.V.
Country
Netherlands (NL)
ATC code
L03AA02
ATC class
Filgrastim
Defined daily dose
0.35 mg, P
Reimbursed
Not published by this register
Source register
CBG-MEB (Netherlands)
Last checked
September 29, 2026

Packs & prices · 1

  • cbg_meb_id
    26387

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

191 interactions on record for filgrastim.

Graded by severity as the source publishes them — 2 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check filgrastim against other medicinesHow interaction checks work

Filgrastim · interactions on record

191 records

  • 2 severe
  • 189 moderate

Most severe, free to view

  • CladribineL01BB04severe
  • CyclophosphamideL01AA01moderate
  • ChlorambucilL01AA02moderate
  • MelphalanL01AA03moderate
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Filgrastim in 18 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All filgrastim products

Authorised across Europe · EMA

The same active substance is authorised in 14 EEA countries. Names it is sold under:

  • Belgium · Neupogen
  • Germany · Neupogen
  • Spain · Neupogen
  • France · Neupogen
  • United Kingdom (Northern Ireland) · Neupogen, Neupogen Singleject
  • Ireland · Neupogen, Neupogen Singleject
  • Iceland · Accofil, Filgrastim Hexal
  • Italy · Granulokine
  • Liechtenstein · Accofil, Filgrastim Hexal
  • Luxembourg · Neupogen
  • Norway · Accofil, Filgrastim Hexal
  • Poland · Neupogen
  • Sweden · Neupogen
  • Slovenia · Neupogen

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/7a6b668c-c1ac-471f-8ebc-77c28e36b752
GET /v1/drugs/7a6b668c-c1ac-471f-8ebc-77c28e36b752?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Oplossing voor injectie",
  "route": "Intraveneus gebruik, Subcutaan gebruik",
  "soort": "RVG",
  "source": "cbg_meb",
  "smpc_url": "https://www.geneesmiddeleninformatiebank.nl/smpc/h26387_smpc.pdf",
  "strength": null,
  "atc_label": "Filgrastim",
  "detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/rvg26387",
  "excipients": [
    "AZIJNZUUR (E 260), GECONCENTREERD",
    "NATRIUMHYDROXIDE (E 524)",
    "POLYSORBAAT 80 (E 433)",
    "SORBITOL (E 420)",
    "WATER VOOR INJECTIE"
  ],
  "substances": [
    "FILGRASTIM"
  ],
  "leaflet_url": "https://www.geneesmiddeleninformatiebank.nl/bijsluiters/h26387.pdf",
  "authorised_at": "2001/07/17",
  "procedure_number": "NL/H/4571/003",
  "dispensing_status": "Uitsluitend recept",
  "registration_number": "26387",
  "additional_monitoring": "N"
}
API referenceMCP serverPlans

See everything about filgrastim.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console